3SBio Inc Shs Unitary 144A/Reg S 83B
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HKD 0.67
- Day Range
- HKD 0.67–0.67
- 52-Week Range
- HKD 0.54–—
- Bid/Ask
- HKD 0.68 / HKD 0.72
- Market Cap
- HKD 1.63 Bil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- 5.95
- Price/Sales
- 1.57
- Dividend Yield (Trailing)
- 1.75%
- Dividend Yield (Forward)
- 4.42%
- Total Yield
- 1.77%
Company Profile
3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Value
- Total Number of Employees
- 5,411
- Website
- https://www.3sbio.com
Comparables
Valuation
|
Metric
|
83B
|
01167
|
02616
|
|---|---|---|---|
Price/Earnings (Normalized) | 5.95 | — | — |
Price/Book Value | 0.89 | 1.17 | — |
Price/Sales | 1.57 | 16.49 | 2.26 |
Price/Cash Flow | 5.23 | — | — |
Price/Earnings
83B
01167
02616
Financial Strength
|
Metric
|
83B
|
01167
|
02616
|
|---|---|---|---|
Quick Ratio | 2.62 | 6.57 | 1.42 |
Current Ratio | 2.88 | 6.57 | 1.56 |
Interest Coverage | 14.79 | −74.95 | −32.18 |
Quick Ratio
83B
01167
02616
Profitability
|
Metric
|
83B
|
01167
|
02616
|
|---|---|---|---|
Return on Assets (Normalized) | 9.33% | −24.28% | −38.51% |
Return on Equity (Normalized) | 15.92% | −31.71% | −157.15% |
Return on Invested Capital (Normalized) | 10.03% | −28.48% | −69.17% |
Return on Assets
83B
01167
02616
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qxwcthvw | Nnbhd | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dybnlwhh | Tbfjtc | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Yynrzfvgv | Yycbq | $99.6 Bil | |
MRNA
| Moderna Inc | Gnswfqhds | Fmvjt | $38.8 Bil | |
ARGX
| argenx SE ADR | Xyvsfpfp | Bklv | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Fksywzjv | Wsdk | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vggzcbyy | Pjcbkj | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qpsvzrnk | Gdhnm | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vspynvxh | Gwprs | $12.4 Bil | |
INCY
| Incyte Corp | Bfnmxlzbl | Lltsvqt | $11.9 Bil |